Reconnecting

The current page stays visible while onset.to reconnects in the background.

HHS Commits Up to $4.9 Million for Ibogaine Research as Compass Completes Psilocybin Application

Open original

HHS announced up to $4.9 million over five years for preparatory ibogaine research and a $20 million funding opportunity for a rapid-acting psychiatric drug research network. The ibogaine funding does not authorize trials or pay for patient treatment, and HHS warned of potentially life-threatening heart rhythm risks. Compass Pathways completed its FDA application for investigational psilocybin for treatment-resistant depression, but submission is not approval. Senate appropriators called for VA planning on psychedelic research in an explanatory statement that is not law. The DEA proposed higher 2027 production quotas for several psychedelics, while California offered up to $4 million for research involving veteran communities.